Background and Aims: The Hepatitis C Virus (HCV) is essentially hepatotropic but virus compartment has also been found in other important extra hepatic sites. Detection of HCV RNA in extra hepatic reservoirs such as peripheral blood mononuclear cells (PBMCs) is important for determining of disease progression and effective treatment. The present study aimed to determine of different HCV genotypes in plasma and PBMCs specimens from patients of Yazd province of Iran. Materials and Methods: Blood samples of 50 patients with established HCV referred to Shahid Sadoughi Hospital were collected. These patients had positive anti-HCV and positive plasma HCV RNA. After RNA extraction from plasma and a pellet of approximately 3-5× 10 6 PBMCs, CDNA synthesis was done and stuck in -70°C. Then HCV genotyping by using of restriction fragment length polymorphisms (RFLPs) method was carried out. Finally, Data analysis was done by SPSS software. Results: The mean age of subjects infected with HCV 38/2±14/6 (ages 21-66) who were the majority of those between ages lower 30 years. 3a and 1a genotype distribution in plasma was significantly higher in those aged over 40 than other age that this difference in genotype distribution at the age of 40 is significant (P value> 0.04) but in PBMCs was not significant (p=0.25). 1a and 3a genotype distribution in plasma and PBMCs in between 40-30 ages showed a lower frequency than other ages. In none of the samples from patients with genotype 2 and 1b genotypes but only 3a and 1a such as mixed infections was detected. Typically, mixing virus infection in 8 patients (16%) in plasma and in 16 samples (32%) was identified in PBMCs. Conclusions: It suggested that plasma subtyping as the target genotype for considering of antiviral therapy is essential, but may be result to the goal of therapy. HCV genotyping in PBMCs samples along with plasma specimen might be beneficial. Therefore, determine of HCV genotype in PBMCs in before therapy because detection of occult infection is useful
Introduction * epatitis C is classified to at least 7 major genotypes that each genotype has several genomic subtype and generally about 67 subtype due to changes in the genome (1). The geographical distribution of HCV genotypes is varied in different regions of world although some strains in some region are endemic (2, 3). Hepatitis C virus is necessarily hepatotropic but replication in other areas such as including in peripheral mononuclear blood cells (PBMCs) of infected people has also been found (4). These cells are including in lymphocytes, Macrophages, and Dendritic cells which are a major component of the immune cells (5). It is shown that virus genotypes in these cells in a patient's infected-HCV may be distinct with circulating strains in the plasma, so suggested that the proliferation in PBMCs is considered as an independent area. The detection of virus genotypes in this area it is possible important the type of transmission, disease progression and treatment regime (6, 7). Hepatitis C virus in PBMCs and liver is proliferating and for this reason many different subtypes of the virus during replication is created so in these two area can be distinct subtype of virus genotypes and two genotypes are varies from this aspect of sequence them together. It is probably due to the different genotypes of the virus in serum and PBMCs can have an impact on the progress of disease recurrence in during and after therapy (6). Therefore, it is essential to determine the HCV genotype in PBMCs before beginning the therapy. The pathological significance and the relationship between HCV RNA serum levels and PBMCs in during and end of therapy are not well known in Iran and low study has been conducted on this subject (8) Patients who were positive for anti-HCV antibodies but negative for HCV RNA were excluded from the study. Anti-HCV detection was performed by a third generation enzyme immunoassay, based on the manufacturers' guidance (DIA.PRO, Diagnostic Bioprobes Srl, Italy). Hepatitis C plasma RNA was detected by PCR method. Plasma samples were kept frozen and stored at -70°C until use. Also, a questionnaire, consisting of the demographic characteristics and risk factors ,as the possible modes of transmission (intra-venous drug abuse, multitransfusion and blood transfusion was completed for each patient. HCV RNA Extraction and cDNA Synthesis. RNA was extracted from 200 µL of plasma, using the AccuPrep Viral RNA Extraction Kit (Bioneer, South Korea). About 5 mL of peripheral blood was kept in EDTA-containing tubes and then the PBMCs were isolated, using Ficoll-Hypaque density gradient centrifugation (Ficoll-Hypaque; Pharmacia, Uppsala, Sweden). The PBMCs were then washed three times with phosphate-buffered saline (pH 7.3±0.1) and counted and then RNA was extracted from a pellet of approximately 5 × 106 PBMCs, then total RNA was prepared from the blood cells after lysis with ammonium chloride and TRizol reagent (Invitrogen, Paisley, UK). The final volume, in the reaction for synthesis of cDNA, was 20 µL, including 5 µL RNA, 1 µL random hexamer (Fermentas GmbH, Germany), 6.5 µL of diethylpyrocarbonate (DEPC) treated water, 4 µL reverse transcriptase reaction buffer 5x, 2 µL dNTP, 10 mM stock, (Fermentase GmbH, Germany), 0.5 µL RNase Inhibitor (Fermentas GmbH, Germany) and 200 IU of reverse transcriptase (Fermentas GmbH, Germany), which was then incubated at 65°C for 5 minutes, 42°C for 60 minutes. HCV Genotyping. HCV genotype was determined using specific-primers of 5'-UTR region of HCV genome have already been published (9) . Each 25 µl reaction mixture contained of 5 µl of template, 2.5 µl of 10X reaction buffer (Applied Biosystems, Foster City, CA), and 1.5 mM MgCl2 (AB), 0.5 mM of each dNTPs (AB), HCV-specific primers, and AmpliTaq DNA polymerase (AB). The amount of specific-HCV primers in each reaction based on the type of primer was different. 2 µL of this cDNA was amplified for 40 cycles with the following parameters: a preliminary 20 cycles of amplification at 94 0C for 1 min (denaturing), 45 0C for 1 min (annealing), and 72 0C for 1 min (extension), followed by 20 additional cycles of 94 0C for 1 min, 60 0C for 1 min, and 72 0C for 1 min. For the second-round PCR, 5 µL of first-round PCR product was amplified for 30 cycles; each cycle consisted of 94 0C for 1 min, 62 0C for 45 s, and 72 0C for 1 min. Finally, the analysis of results was performed on the basis of the presence or absence of specific bands of amplified DNA in the 2% agarose gel (Fig.1) . Statistical Analysis. Analysis was performed using the Statistical Package for Social Sciences (SPSS) software version 17.0, using descriptive values such as mean, standard deviation and Fisher's exact probability test. P value<0.05 was considered statistically significant.
Results
The average age of the 50 HCV infectedpeople were 14.6±38.2 (ages 21-66) was that most people were between ages 50-41 years. The majority of participants were males (82.5%) and the rest of females (17.5%). The frequency distribution of genotypes in plasma of PCR products were 338 bp for genotype 1a, 398 bp for 1b, 286 bp for 2 and 227 bp for 3a (10) .
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4 Iranian Journal of Virology, Volume 9, Number 2, 2015 and PBMCs you can see in Table 1 . Genotype distribution in plasma and PBMCs are different in some cases Table 2 . In none of the samples from patients with genotype 2 and 1b were detected but genotype 3a and 1a were detected along with mixed infections. Mixed infection with genotype 3a and 1a in 8 patients (16%) in plasma and in 16 samples (32%) in PBMCs was detected.
PCR and HCV genotyping:
Genotyping of 50 sera from patients who were either recently infected by HCV or with history of previous HCV infection and positive PCR results was performed. The first, all of samples due to HCV detection was check using Nested-PCR that the size product was 174 bp (Figure 1) . Then The HCV genotypes were determined in all 50 positive PCR patients based on HCV (Figure 2) . HCV genotype distribution based on different age groups: Plasma. 1a and 3a genotype distribution was in over 40 years higher than in other ages that this difference with other ages was significant (P Value> 0.04). Distribution of the genotypes 1a and 3a as well as between the ages of 40-30 years showed the lowest frequency than other ages. The distribution of different genotypes of HCV in plasma of different ages was shown in Table 3 . PBMCs. 1a and 3a genotype distribution was in over 40 years higher than in other ages but this difference with other ages was not significant (P=0.25). Distribution of the genotypes 1a and 3a as well as between the ages of 40-30 years showed the lowest frequency than other ages. HCV genotypes distribution in PBMCs of different ages can be seen in Table 4 .
Discussion
In the recent study, we were evaluated the genotype of the virus in plasma and PBMCs samples in 50 patients infected to HCV. In our study, it was shown that the prevalence of genotype 1a and 3a is higher in patients over age 30 that were different from that obtained in other studies in Iran but was similar to other study (11) which can be due to small sample size in the study (12, 13) . The distribution of HCV genotype in plasma and PBMCs are different in some cases but HCV genotypes were detected to all plasma and PBMCs that were reported in previous studies (13, 14) . Mix genotype was detected in eight plasma samples and 16 samples of PBMCs. Mixed infection is a person when has two or more distinct genotypes of HCV virus is at the same time. Mix viral infection has clinical importance, for example, may lead to exacerbation, treatment failure or relapse after completion of the disease. This means that the PBMCs may contain various genotypes that cannot be detected in plasma. Previous studies have concluded that the PBMCs as a place extrahepatic replication that is confirmed (14) . Several studies in HCV-infected patients have shown that the genome of the virus in other locations as the site of viral replication in the liver, such as PBMCs after completion of treatment was detected (15) (16) (17) . In fact, this achievement stressed that infection with one genotype is no longer a barrier to infect with another genotype. So, multiple contacts with HCV, especially with high risk people such as hemophilia, thalassemia, may lead to re-infection and the stability of mixed infection in some patients (18) . Also superinfection with a new type may be to suppress a HCV virus and this type was as dominant type of treatment therefore this event may alter treatment outcome. In our study, the prevalence of mixed infections in 8 patients (16%) in plasma and in 16 samples (32%) in PBMCs was estimated in individuals infected with HCV. Previous studies was indicated there has been evidence of persisting HCV RNA in PBMCs despite sustained clearance of HCV RNA from serum (19) . Mixed infection with two different genotypes and in others with a different genotype than in serum was detected in PBMCs. In other studies, the rate of 6.1% to 31% in hemophiliacs has been detected with high transfusion (20) . Studies, mixed infections was concluded that 15% of patients with different genotypes, also in another study investigated 2.5% of mixed infections in plasma was detected. Our study showed that a significant proportion of people infected with HCV genotypes are different in the PBMCs over plasma. Our study had some limitations, including the lack of liver biopsy noted that was hazard because liver biopsy is the main place HCV replication. Since liver biopsy can be performed for all patients is not recommended due to the different genotypes of the virus have been detected in PBMCs over plasma PBMCs that can be used as a reservoir for assess of infection.
Conclusion
Our study suggests that we should be assessment mix infection in patients with high transfusion using examining PBMCs. Because according to the results we can say that the lack of response to treatment or recurrent disease is caused by a lack of adequate knowledge of the genotype of the virus. So, evaluate genotypes of HCV virus in PBMCs samples as a complementary tool can be help to for treatment planning.
